Aydin Huseynov

The recent downturn in Incyte Corporation’s (NASDAQ: INCY) share price offers an entry opportunity, with the FDA likely to approve ruxolitinib in chronic GVHD indication in September 2021, according to Benchmark. The Incyte Analyst: Aydin Huseynov upgraded the rating for Incyte to Buy, while...

A day after short seller Citron Research slammed Inovio Pharmaceuticals Inc (NASDAQ: INO), sell-side analysts lined up behind the company.  Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus...